2021. Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s4. DOI:https://doi.org/10.25251/skin.5.supp.4.